Integer Holdings Corporation (ITGR) fundamentals score
Over the past several years, Integer has evolved its portfolio strategy to focus on higher growth medtech markets where it possesses differentiated capabilities. Integer continues to execute a tuck-in acquisition strategy that has added capabilities, leading brands and complementary technologies, increased customer penetration, and enhanced scale in its targeted growth markets.
Electromedical & Electrotherapeutic Apparatus · Healthcare · Listed on NYSE
Overall: 6.2 out of 10, Mixed fundamentals
- Growth: 5.7/10
- Profitability: 4.5/10
- Financial health: 6.5/10
- Earnings quality: 8.8/10
- Valuation: 6.9/10
Scores are calculated from Integer Holdings Corporation’s SEC filings, using the 12 months through 2026-07. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10